El interés en corto de Arcutis Biotherapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Arcutis Biotherapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Arcutis Biotherapeutics (NASDAQ:ARQT) Bolsa, Informe de interés en corto

ARCUTIS BIOTHERAPEUTICS INC

Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARQT

ATPC

BDTX

DRCT

GCTK

ITCI

LAES

LDTC

QBTS

QMMM

RGTI

RIME

SAGE

STAI

TRAW

VMAR

Sage Therapeutics sube 34% tras oferta de Biogen. Conoce los mayores ganadores y perdedores del premercado de EE.UU.

Las acciones de Sage Therapeutics (SAGE) se disparan un 34%; 20 acciones que se mueven en premercado

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics Inc

WIIM

SMPL

The Simply Good Foods Company shares are trading higher after the company reported better-than-expected Q2 financial results.

Jefferies analyst Stephanie Moore maintains CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) with a Buy and lowers the price target from $37 to $33.

Price Target

Analyst Ratings

Jefferies Maintains Buy on CSX, Lowers Price Target to $33

Keybanc analyst Justin Patterson maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Overweight and lowers the price target from $1100 to $1000.

NFLX

Keybanc Maintains Overweight on Netflix, Lowers Price Target to $1000

Jefferies analyst Stephanie Moore maintains Canadian National Railway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNI#NYSE">CNI</a>) with a Buy and lowers the price target from $120 to $110.

Jefferies Maintains Buy on Canadian National Railway, Lowers Price Target to $110

KRUS

Kura Sushi USA shares are trading higher. The company reported its Q2 financial results.

Keybanc analyst Justin Patterson maintains Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Overweight and lowers the price target from $41 to $37.

PINS

Keybanc Maintains Overweight on Pinterest, Lowers Price Target to $37

PHIO

Phio Pharmaceuticals  Shares Halted On Circuit Breaker To The Downside, Stock Now Up 72.3%

<a href="https://www.bloomberg.com/latest?utm_source=homepage&amp;utm_medium=web&amp;utm_campaign=latest" title="https://www.bloomberg.com/latest?utm_source=homepage&amp;utm_medium=web&amp;utm_campaign=latest">https://www.bloomberg.com/latest?utm_source=homepage&amp;utm_medium=web&amp;utm_campaign=latest</a>

AMZN

'Amazon Seeks Partners for $15 Billion Warehouse Expansion Plan' - Bloomberg News

Jefferies analyst Stephanie Moore maintains Canadian Pacific Kansas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) with a Buy and lowers the price target from $100 to $90.

Jefferies Maintains Buy on Canadian Pacific Kansas, Lowers Price Target to $90

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares are volatile Wednesday following a multi-day slide as trade tensions between the United States and China <a href="https://www.benzinga.com/25/04/44708103/why-investors-should-watch-chinas-service-trade-amid-us-tariff-escalation-disney-and-imax-most-impacted">continue to rise</a>. 
What To Know: President Donald Trump&#8217;s sweeping reciprocal tariffs went into effect on Wednesday, which included a massive 104% tariff on goods from China. 
China has responded again by hiking its tariffs on U.S. imports to 84% from 34%, starting April 10, according to a <a href="https://www.cnbc.com/2025/04/09/china-slaps-retaliatory-tariffs-of-84percent-on-us-goods-in-response-to-trump.html">CNBC</a> report citing an <a href="https://gss.mof.gov.cn/gzdt/zhengcejiedu/202504/t20250409_3961685.htm" target="_blank" rel="noreferrer noopener">announcement</a> from the Office of the Tariff Commission of the State Council.
The back-and-forth tariff increases have furthered the trade war between the world&#8217;s two largest economies.
&#8220;It's unfortunate that the Chinese actually don't want to come and negotiate, because they are the worst offenders in the international trading system,&#8221; U.S. Treasury Secretary Scott Bessent reportedly said in a Fox Business interview on Wednesday.
&#8220;They have the most imbalanced economy in the history of the modern world, and I can tell you that this escalation is a loser for them.&#8221;
Apple assembles about 90% of its iPhones in China. Analysts have estimated&nbsp;that the price of an iPhone could rise by $250 or more as a result of new tariffs.
&#8220;There are no winners in a trade war,&#8221; China&#8217;s commerce ministry reportedly said in a statement. &#8220;China does not want one, but the government will never allow the legitimate rights and interests of the Chinese people to be harmed or taken away.&#8221;
Check This Out: <a href="https://www.benzinga.com/news/global/25/04/44706519/apple-stock-nosediving-since-liberation-day-tariffs-has-created-panic-says-gene-munster-predicts-tim-cooks-favorable-relationship-with-trump-xi-jinping-will-rescue-iphone-maker">Apple Stock Nosediving Since &#8216;Liberation Day&#8217; Tariffs Has Created Panic, Says Gene Munster: Predicts Tim Cook&#8217;s &#8216;Favorable&#8217; Relationship With Trump, Xi Jinping Will Rescue iPhone-Maker</a>
Jefferies analyst Edison Lee on Wednesday upgraded Apple from Underperform to Hold and lowered the price target from&nbsp;$202.33&nbsp;to&nbsp;$167.88.
Deepwater Asset Management&#8217;s Gene Munster said this week that Apple shares have fallen into <a href="https://x.com/munster_gene/status/1909707386706710929?ref_src=twsrc%5Etfw">&#8220;panic mode&#8221;</a> as relations with China are set to become &#8220;ugly&#8221; over the next month. However, the analyst expects Apple to be &#8220;largely spared&#8221; from tariffs given CEO Tim Cook&#8217;s favorable relationship with both Trump and Chinese President&nbsp;Xi Jinping.
&#8220;Big picture: This storm will pass. Apple's brand loyalty remains strong—and will drive an Apple Intelligence upgrade cycle in FY26,&#8221; Munster said. 
AAPL Price Action: <a href="http://benzinga.com/quote/aapl">Apple shares</a> were up 3.51%% at $178.48 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Global

AAPL

What's Going On With Apple Stock Wednesday?

<ul>
<li>eBay Ventures, eBay's venture capital arm, has awarded US business Refiberd USD$300,000 investment crowning them eBay's Circular Fashion Innovator of the Year. &nbsp;</li>
<li>By the end of 2025, eBay will have provided a global investment of $1.2 million to fashion innovators and small businesses through its global Circular Fashion Fund, designed to support start-ups to scale circular solutions—from production to end-of-life, including rental and repair services. &nbsp;</li>
<li>The fund sees eBay partner with the fashion industry's foremost councils—British Fashion Council (BFC), Council of Fashion Designers of America (CFDA), Fashion Council Germany (FCG) and Australia Fashion Council (AFC)—giving recipients access and visibility to propel growth.</li>
</ul>
SAN JOSE, Calif., April 9, 2025 /PRNewswire/ --&nbsp;Today, global marketplace and leading destination for branded pre-loved fashion, eBay, is investing USD$300,000 into <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4401697-1&amp;h=986393748&amp;u=https%3A%2F%2Frefiberd.com%2F&amp;a=Refiberd">Refiberd</a> in its ongoing efforts to support fashion startups to scale circular solutions through its global Circular Fashion Fund program.&nbsp;
Refiberd was announced the winner of eBay's Circular Fashion Innovator of the Year Award which saw 12 shortlisted businesses across the UK, US, Germany, and Australia rewarded for their work in pioneering a more circular fashion industry.
This funding is aimed to scale the impact of Refiberd's cutting-edge AI system that can discern exactly what different fabrics are made of, allowing them to be accurately sorted and recycled. Their technology can be integrated into existing recycling infrastructures to sort materials and ensure they're processed using the right methods—helping recyclers turn textile waste into new, usable fibers. By enabling more efficient recycling, Refiberd aims to tackle the industry's waste-sorting dilemma and drive true circularity in fashion.
Since the Circular Fashion Fund's launch in 2022, it has supported 27 businesses and by the end of 2025 will have invested a total of $1.2 million alongside over 200 hours of mentoring and upskilling from industry experts. In partnership with the fashion's foremost councils—BFC, CFDA, FCG, and AFC—eBay gives recipients unprecedented access and visibility into the industry to propel their business's growth.
eBay has championed recommerce since its inception and the fund is one of the many ways it continues to invest in tools and technology that fuel the circular economy and help drive the fashion industry to a more sustainable future. As appetite for circular fashion continues to increase, with 66% of Gen Zs saying that purchasing pre-loved fashion has grown in personal importance&#x2A;—eBay's Circular Fashion Fund comes at a pivotal time for the industry.

EBAY

eBay Ventures Awards Refiberd $300,000 As Circular Fashion Innovator Of The Year, Pledging $1.2M Global Investment By 2025 To Support Fashion Startups In Scaling Circular Solutions And Tackling Textile Waste With AI Technology

Byrna Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-04-10. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Byrna Technologies will report an earnings per share (EPS) of $0.01.
The market awaits Byrna Technologies's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.16, leading to a 0.0% drop in the share price on the subsequent day.
Here's a look at Byrna Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.05</td>
<td>0.05</td>
<td>0.03</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.21</td>
<td>0.08</td>
<td>0.12</td>
<td>0</td>
</tr>
<tr>
<td>Price Change %</td>
<td>8.0%</td>
<td>-3.0%</td>
<td>-7.000000000000001%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744207302_0.png" alt="eps graph" />
<h3>Byrna Technologies Share Price Analysis</h3>
Shares of Byrna Technologies were trading at $15.07 as of April 08. Over the last 52-week period, shares are up 2.15%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BYRN/earnings">To track all earnings releases for Byrna Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

BYRN

A Look at Byrna Technologies's Upcoming Earnings Report

Keybanc analyst Justin Patterson maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Overweight and lowers the price target from $675 to $625.

SPOT

Keybanc Maintains Overweight on Spotify Technology, Lowers Price Target to $625

Jefferies analyst Stephanie Moore maintains Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Hold and lowers the price target from $255 to $230.

Jefferies Maintains Hold on Union Pacific, Lowers Price Target to $230

Bank7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSVN#NASDAQ">BSVN</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-04-10. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Bank7 will report an earnings per share (EPS) of $0.95.
Anticipation surrounds Bank7's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.11 in the last quarter, leading to a 0.22% drop in the share price on the following day.
Here's a look at Bank7's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.05</td>
<td>1.07</td>
<td>1.04</td>
<td>1.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.16</td>
<td>1.24</td>
<td>1.23</td>
<td>1.21</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>7.000000000000001%</td>
<td>5.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744207288_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Bank7 were trading at $35.79 as of April 08. Over the last 52-week period, shares are up 31.92%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BSVN/earnings">To track all earnings releases for Bank7 visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSVN

A Glimpse of Bank7's Earnings Potential

In the last three months, 13 analysts have published ratings on Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $65.38, along with a high estimate of $72.00 and a low estimate of $48.00. This current average reflects an increase of 1.05% from the previous average price target of $64.70. 
<img src="https://www.benzinga.com/files/images/story/2025/1744207282_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Avidity Biosciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joseph Stringer &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $60.00&#x7C;$60.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Joseph Stringer &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $60.00&#x7C;$60.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Keay Nakae &#x7C;Chardan Capital &#x7C;Maintains &#x7C;Buy &#x7C; $65.00&#x7C;$65.00 &#x7C; 
&#x7C;Geoff Meacham &#x7C;Citigroup &#x7C;Announces &#x7C;Buy &#x7C; $70.00&#x7C;- &#x7C; 
&#x7C;Kostas Biliouris &#x7C;BMO Capital &#x7C;Announces &#x7C;Outperform &#x7C; $72.00&#x7C;- &#x7C; 
&#x7C;Geoff Meacham &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $48.00&#x7C;$51.00 &#x7C; 
&#x7C;Louise Chen &#x7C;Scotiabank &#x7C;Announces &#x7C;Sector Outperform&#x7C; $70.00&#x7C;- &#x7C; 
&#x7C;Gena Wang &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $57.00&#x7C;$63.00 &#x7C; 
&#x7C;Keay Nakae &#x7C;Chardan Capital &#x7C;Maintains &#x7C;Buy &#x7C; $65.00&#x7C;$65.00 &#x7C; 
&#x7C;Luca Issi &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $67.00&#x7C;$67.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Avidity Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Avidity Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Avidity Biosciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Avidity Biosciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Avidity Biosciences analyst ratings.</a>
<h2>Unveiling the Story Behind Avidity Biosciences</h2>
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
<h3>Financial Insights: Avidity Biosciences</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Avidity Biosciences showcased positive performance, achieving a revenue growth rate of 35.57% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Avidity Biosciences's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -3439.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Avidity Biosciences's ROE stands out, surpassing industry averages. With an impressive ROE of -6.98%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Avidity Biosciences's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.38%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Avidity Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock

Northern Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTIC#NASDAQ">NTIC</a>) is preparing to release its quarterly earnings on Thursday, 2025-04-10. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Northern Technologies to report an earnings per share (EPS) of $0.06.
The announcement from Northern Technologies is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.05, leading to a 0.0% drop in the share price on the subsequent day.
Here's a look at Northern Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.12</td>
<td>0.19</td>
<td>0.24</td>
<td>0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.07</td>
<td>0.20</td>
<td>0.11</td>
<td>0.18</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>-1.0%</td>
<td>-7.000000000000001%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744207276_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Northern Technologies were trading at $9.25 as of April 08. Over the last 52-week period, shares are down 32.73%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/NTIC/earnings">To track all earnings releases for Northern Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTIC

Insights into Northern Technologies's Upcoming Earnings

In the last three months, 4 analysts have published ratings on Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Fortrea Holdings and provided 12-month price targets. The average target is $12.0, accompanied by a high estimate of $15.00 and a low estimate of $10.00. Experiencing a 39.24% decline, the current average is now lower than the previous average price target of $19.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1744207270_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Fortrea Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Lowers &#x7C;Neutral &#x7C; $10.00&#x7C;$12.00 &#x7C; 
&#x7C;Elizabeth Anderson &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;In-Line &#x7C; $15.00&#x7C;$20.00 &#x7C; 
&#x7C;Matthew Sykes &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $11.00&#x7C;$22.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $12.00&#x7C;$25.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Fortrea Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Fortrea Holdings compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Fortrea Holdings's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Fortrea Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FTRE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Fortrea Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Fortrea Holdings</h2>
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
<h3>Financial Insights: Fortrea Holdings</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Fortrea Holdings's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -1.79%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -8.78%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Fortrea Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -4.26%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Fortrea Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.69% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Fortrea Holdings's debt-to-equity ratio is below the industry average at 0.88, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FTRE

Demystifying Fortrea Holdings: Insights From 4 Analyst Reviews

Morgan Stanley analyst Terence Flynn maintains Organon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) with a Equal-Weight and lowers the price target from $16 to $15.

Morgan Stanley Maintains Equal-Weight on Organon, Lowers Price Target to $15

CureVac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) is set to give its latest quarterly earnings report on Thursday, 2025-04-10. Here's what investors need to know before the announcement.
Analysts estimate that CureVac will report an earnings per share (EPS) of $-0.09. 
Investors in CureVac are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.84, which was followed by a 4.51% drop in the share price the next day.
Here's a look at CureVac's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.60</td>
<td>-0.29</td>
<td>-0.26</td>
<td>-0.20</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.24</td>
<td>-0.32</td>
<td>-0.33</td>
<td>-0.41</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-0.0%</td>
<td>-7.000000000000001%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744207265_0.png" alt="eps graph" />
<h3>Market Performance of CureVac's Stock</h3>
Shares of CureVac were trading at $2.72 as of April 08. Over the last 52-week period, shares are down 6.93%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CVAC/earnings">To track all earnings releases for CureVac visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVAC

Insights Ahead: CureVac's Quarterly Earnings

Health Care

Press Releases

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

General

U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age

Comments

Arcutis Biotherapeutics

Interés en corto

Arcutis Biotherapeutics (NASDAQ:ARQT) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL